Algorithm for codevelopment of new drug-predictive biomarker combinations: Accounting for inter- and intrapatient tumor heterogeneity

Clinical Lung Cancer

Volumn 13, Issue 5, 2012, Pages 321-325

  Gandara, David R ^a   Li, Tianhong ^a   Lara, Primo N ^a   MacK, Philip C ^a   Kelly, Karen ^a   Miyamoto, Suzanne ^a   Goodwin, Neal ^b   Beckett, Laurel ^a   Redman, Mary W ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Jackson Laboratories (JAX WEST)   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Codevelopment; Heterogeneity; Personalized therapy

Indexed keywords

ANTINEOPLASTIC AGENT; APRINOCARSEN; BEVACIZUMAB; BEXAROTENE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIGITUMUMAB; GEFITINIB; LONAFARNIB; MATRIX METALLOPROTEINASE; PANITUMUMAB; PF 351; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE C ALPHA; RETINOID X RECEPTOR; SORAFENIB; TOLL LIKE RECEPTOR 9; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VADIMEZAN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ALGORITHM; BREAST CANCER; CANCER SURVIVAL; CELL HETEROGENEITY; HUMAN; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 84865456673     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.05.004     Document Type: Note

References (21)

1. D.R. Gandara, P.N. Lara Jr, P. Mack Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making Clin Lung Cancer 10 2009 148 150
2. T. Tursz, F. Andre, V. Lazar Implications of personalized medicine: perspective from a cancer center Nat Rev Clin Oncol 8 2011 177 183
3. S. Roychowdhury, M.K. Iyer, D.R. Robinson Personalized oncology through integrative high-throughput sequencing: a pilot study Sci Transl Med 3 2011 111 121
4. R. Pirker, J.R. Pereira, A. Szczesna FLEX Study Team Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
5. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
6. T.Z. Mok, Y.-L. Wu Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
7. M. Soda, Y.L. Choi, M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
8. A.T. Shaw, B.Y. Yeap, B.J. Soloman Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
9. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
10. K. Shedden, J.M. Taylor Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Nat Med 14 2008 822 827
11. A. Subramanian, P. Tamayo, V.K. Mootha Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci U S A 102 2005 15545 15550
12. W. Lee, Z. Jiang, J. Liu The mutation spectrum revealed by paired genome sequences from a lung cancer patient Nature 465 2010 473 477
13. B. Johnson, M.G. Kris, D. Kwiatkowski Clinical characteristics of planned 1000 patients with adenocarcinoma of lung (ACL) undergoing genomic characterization in the US Lung Cancer Mutation Consortium (LCMC) J. Thor, Oncology, Proc 14th World Conf on Lung Cancer 6 2011 S344
14. M.D. Pegram, R. Pietras, A. Bajamonde Targeted therapy: wave of the future J Clin Oncol 23 2005 1776 1781
15. D.R. Gandara, T. Van Dyke, Z. Weaver-Ohler Enhancing EGFR-directed therapies through a novel research platform integrating data from genetically engineered mice, patient derived xenografts and clinical trials (iGXT) J Thor Oncol, Proc 14th World Conf on Lung Cancer 6 2011 S41
16. D.J. Sargent, B.A. Conley, C. Allegra Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 2005 2020 2027
17. A. Hoering, M. LeBlanc, J.J. Crowley Randomized phase III clinical trial designs for targeted agents Clin Cancer Res 14 2008 4358 4367
18. S.J. Mandrekar, D.J. Sargent Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges J Clin Oncol 27 2009 4027 4034
19. R. Simon, A. Maitournam Evaluating the efficiency of targeted designs for randomized clinical trials Clin Cancer Res 10 2004 6759 6763
20. Y. Iwasa, F. Michor Evolutionary dynamics of intratumor heterogeneity PLoS ONE 6 2011 e17866
21. R.C. Doebele, A.B. Pilling, D. Aisner Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell Lung Cancer 18 2012 1472 1482